**Supplementary Table S2:** Ocular (study eye) and nonocular adverse events leading to permanent study treatment discontinuation, regardless of study treatment relationship, by primary system organ class and preferred term (safety set)

<table>
<thead>
<tr>
<th>Primary system organ class</th>
<th>Preferred term, n (%)</th>
<th>T&amp;E ranibizumab 0.5 mg+laser n=126</th>
<th>T&amp;E ranibizumab 0.5 mg n=126</th>
<th>PRN ranibizumab 0.5 mg n=118</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ocular AEs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any primary system organ class</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Macular fibrosis</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Nonocular AEs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any primary system organ class</td>
<td>9 (7.1)</td>
<td>6 (4.8)</td>
<td>5 (4.2)</td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Bradycardia</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>1 (0.8)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Myocardial ischemia</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Intervertebral disc protrusion</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Spinal osteoarthritis</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</strong></td>
<td>2 (1.6)</td>
<td>0 (0.0)</td>
<td>2 (1.7)</td>
<td></td>
</tr>
<tr>
<td>Hepatic cancer</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Pancreatic carcinoma</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Lung adenocarcinoma</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Metastases to peritoneum</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td>1 (0.8)</td>
<td>2 (1.6)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular accident</td>
<td>1 (0.8)</td>
<td>1 (0.8)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Haematuria</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Renal mass</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorder</strong></td>
<td>1 (0.8)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Acute respiratory failure</td>
<td>0 (0.0)</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
</tbody>
</table>

Safety set consisted of all patients who received at least one active application of study treatment and had at least one post-baseline safety assessment.

Percentages are based on the number of patients in the Safety set in the specific treatment group.

AEs, adverse events; PRN, pro re nata; T&E, treat-and-extend.